Suppliers and packagers for EXONDYS 51

EXONDYS 51

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488	NDA	Sarepta Therapeutics, Inc.	60923-284-10	1 VIAL, SINGLE-USE in 1 CARTON (60923-284-10) / 10 mL in 1 VIAL, SINGLE-USE	2016-09-19
Sarepta Theraps Inc	EXONDYS 51	eteplirsen	SOLUTION;INTRAVENOUS	206488	NDA	Sarepta Therapeutics, Inc.	60923-363-02	1 VIAL, SINGLE-USE in 1 CARTON (60923-363-02) / 2 mL in 1 VIAL, SINGLE-USE	2016-09-19

Suppliers for EXONDYS 51 (eteplirsen): Who manufactures, supplies, and controls access to supply and IP

Last updated: May 25, 2026

EXONDYS 51 is marketed as eteplirsen, an exon-skipping antisense oligonucleotide (ASO) indicated for Duchenne muscular dystrophy (DMD) patients with a confirmed mutation amenable to exon 51 skipping. The supplier picture is dominated by the manufacturer of record for the drug substance (ASO) and the drug product, plus the companies supplying critical raw materials and specialized manufacturing services for sterile, oligonucleotide-based drug product. For U.S. supply and market access planning, the operative suppliers are the listed manufacturers on the U.S. label (and their CMO/manufacturing-partner chain) and the companies holding regulatory and patent rights tied to eteplirsen.

Who manufactures EXONDYS 51 (eteplirsen) for the U.S. market?

Featured snippet: EXONDYS 51 is developed and commercialized by Sarepta Therapeutics; the U.S. label identifies the manufacturing sites/companies responsible for drug substance and drug product.

Which company is the marketing authorization holder?

• Sarepta Therapeutics, Inc. is the label holder for EXONDYS 51 in the U.S.

What are the key manufacturing roles that define “suppliers”?

For a specialized ASO like eteplirsen, “suppliers” usually breaks into four supply-chain control points:

1. Drug substance manufacture (ASO synthesis and oligonucleotide purification)
2. Drug product manufacture (formulation, sterile filtration/fill-finish, packaging)
3. Quality release testing (analytical and stability release testing capacity)
4. Critical reagents and consumables (phosphoramidites, coupling reagents, chromatography media, sterile fill-finish consumables)

What suppliers are listed on the EXONDYS 51 label for drug substance and drug product?

Featured snippet: The label’s “Manufactured for” and related manufacturing sections identify the responsible manufacturers and sites. These are the primary supplier targets for procurement, biosimilar/alternative development, and contingency supply planning.

How to map label manufacturing to procurement action

• Drug substance supplier: Procure through the company or its CMO only if Sarepta/contract terms allow third-party supply.
• Drug product supplier: Used for finished goods procurement, clinical bridging batches, and future line extensions.
• Release testing supplier: Impacts lot release timelines and supply continuity.

What supplier categories are most likely constrained for ASOs?

• Specialized oligonucleotide synthesis capacity (scale, purification, and control)
• cGMP sterile fill-finish capacity (aseptic filling for ASO formulations)
• Chromatography and purification consumables with tight vendor qualification windows
• Analytical methods for ASO identity, purity, and aggregation control (requires validated method transfer)

What patents and exclusivity affect the supplier landscape for EXONDYS 51?

Featured snippet: Market access is constrained by composition, formulation, and use patents, plus regulatory exclusivity tied to the original approval pathway, limiting viable generic/alternative suppliers during the exclusivity window.

Which patent estate blocks alternative suppliers?

For ASOs, the supplier landscape is shaped by:

• Composition of matter (eteplirsen and key chemical/structural definitions)
• Sequence-related claims (ASO sequence and specific modifications that preserve exon-skipping function)
• Formulation and manufacturing-process claims (stability, excipients, fill-finish conditions)
• Method-of-use claims (exon 51 skipping and DMD treatment parameters)

How does regulatory exclusivity interact with supply?

• If exclusivity remains in force, even if another manufacturer can synthesize ASO, the sponsor’s exclusivity blocks FDA approval of a competing product route.
• If exclusivity has passed, alternative manufacturers may still face patent litigation risk.

When does EXONDYS 51 lose exclusivity, and what does that mean for new suppliers?

Featured snippet: EXONDYS 51’s timeline is driven by the original FDA approval date, any pediatric exclusivity, and patent expiration. After exclusivity and key patents expire or are cleared via settlement/Paragraph IV, additional suppliers can compete.

How to interpret “supplier entry timing” for ASO therapeutics

Even when regulatory exclusivity ends, supplier entry typically depends on:

• Patent expiry and/or license/sale agreements
• Manufacturing transfer feasibility (ASO synthesis and purification method transfer)
• Lot release testing capacity and method validation
• FDA review readiness of the ANDA/505(b)(2)-type pathway (as applicable)

How many alternative manufacturing suppliers could realistically enter EXONDYS 51?

Featured snippet: For a complex exon-skipping ASO, the number of realistic new suppliers is usually small because entry requires ASO-specific chemistry capability, validated purification, and sterile drug product operations.

What would a “new supplier” have to replicate?

• Identical or highly comparable oligonucleotide sequence and physicochemical profile
• Stability of the final drug product under specified storage conditions
• Validated, scalable manufacturing under cGMP controls
• Robust analytical release assays matched to FDA expectations for ASOs

What patent litigation affects EXONDYS 51 supply and supplier entry?

Featured snippet: Patent litigation determines whether alternative suppliers can launch without infringing, enter under licensing, or wait for patent expiry.

What litigation outcomes typically change supplier access?

• Settlement agreements granting market entry dates or licensing
• Court rulings narrowing/invalidating claims
• Consent decrees and final judgments that shape redesign or “non-infringing” pathways

How litigation influences manufacturing strategy

• Alternative manufacturers may invest only after a cleared entry window is visible.
• Some entrants produce “design-around” versions, which still can take time and cost due to regulatory comparability.

What is the Orange Book status of EXONDYS 51?

Featured snippet: The Orange Book lists approved drug products with associated patents for the listed NDA, which is the standard map for exclusivity and patent barriers.

What you use Orange Book listings for

• Identify composition/formulation/method patents covering eteplirsen and the approved dosage form
• Determine which patents are likely to be asserted in a Paragraph IV challenge
• Build launch and licensing timelines for new suppliers

What dosage forms and strengths influence the supplier chain for EXONDYS 51?

Featured snippet: EXONDYS 51 is supplied as an injection (ASO drug product) with defined concentration and dosing schedule; the fill-finish configuration constrains “drop-in” substitution.

Manufacturing implications

• Container-closure system and aseptic fill-finish approach affect vendor qualification
• Stability and aggregation control drive formulation and purification controls
• Lot release testing requirements drive testing capacity bottlenecks

How does EXONDYS 51 compare with other exon-skipping ASO competitors for supplier readiness?

Featured snippet: Competing exon-skipping drugs with similar ASO manufacturing constraints show that supply readiness is tied to a small set of ASO-capable CDMOs/CMOs and validated oligonucleotide chemistry lines.

Key comparison dimensions

• Shared CDMO capacity constraints across ASO portfolios
• Differences in formulation, fill-finish approach, and analytical panel complexity
• Patent estate breadth and whether it covers process and formulation in addition to sequence

Key Takeaways

• EXONDYS 51’s supplier ecosystem centers on Sarepta Therapeutics as sponsor and on the drug substance and drug product manufacturers named in the U.S. label.
• For new supplier entry, patent estate scope and FDA-listed patents/exclusivity control whether additional ASO manufacturers can obtain regulatory approval and commercial supply.
• ASO-specific chemistry capability, purification, and sterile fill-finish capacity are the primary operational constraints that limit supplier count.
• Orange Book patent listings and any patent litigation outcomes define practical timelines for supplier diversification.

FAQs

1. Who controls commercialization of EXONDYS 51 in the U.S.?
2. Which parts of the EXONDYS 51 supply chain are most constrained for ASO manufacturing?
3. How does the Orange Book patent list for EXONDYS 51 determine alternative supplier entry timing?
4. Do EXONDYS 51 patent claims cover formulation and manufacturing processes or only the eteplirsen sequence?
5. What litigation milestones would most affect when a competing supplier could launch eteplirsen?

References (APA)

1. Sarepta Therapeutics, Inc. EXONDYS 51 (eteplirsen) Prescribing Information. U.S. FDA.
2. U.S. Food and Drug Administration. Drugs@FDA: EXONDYS 51 (eteplirsen).
3. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations for EXONDYS 51 (eteplirsen).